Results 31 to 40 of about 2,024 (91)

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance

iScience, 2021
Summary: The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of
Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, Timir Tripathi   +3 more
doaj   +1 more source

Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized patients with COVID-19: real-world data from a resource-limited country

International Journal of Infectious Diseases, 2023
Objectives: Georgia introduced remdesivir for the treatment of COVID-19 in December 2020. We evaluated the real-world effect of remdesivir on mortality and the need for mechanical ventilation among inpatients with COVID-19.
Revaz Metchurtchlishvili, Nikoloz Chkhartishvili, Akaki Abutidze, Marina Endeladze, Marine Ezugbaia, Ana Bakradze, Tengiz Tsertsvadze   +6 more
doaj   +1 more source

Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction

Communications Biology, 2023
Remdesivir is an antiviral drug used for COVID-19 treatment worldwide. Cardiovascular side effects have been associated with remdesivir; however, the underlying molecular mechanism remains unknown.
Akiko Ogawa, Seiya Ohira, Yuri Kato, Tatsuya Ikuta, Shota Yanagida, Xinya Mi, Yukina Ishii, Yasunari Kanda, Motohiro Nishida, Asuka Inoue, Fan-Yan Wei   +10 more
doaj   +1 more source

Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition

Frontiers in Microbiology, 2020
Human enteroviruses are responsible for diverse diseases, from mild respiratory symptoms to fatal neurological complications. Currently, no registered antivirals have been approved for clinical therapy.
Wei Ye, Min Yao, Yangchao Dong, Chuantao Ye, Dan Wang, He Liu, Hongwei Ma, Hui Zhang, Libin Qi, Yuewu Yang, Yuan Wang, Liang Zhang, Linfeng Cheng, Xin Lv, Zhikai Xu, Yingfeng Lei, Fanglin Zhang   +16 more
doaj   +1 more source

Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID‐19

Pharmacology Research & Perspectives, 2021
Both antiviral treatment with remdesivir and hemoadsorption using a CytoSorb® adsorption device are applied in the treatment of severe COVID‐19. The CytoSorb® adsorber consists of porous polymer beads that adsorb a broad range of molecules, including ...
Paul Biever, Dawid L. Staudacher, Michaela J. Sommer, Hannah Triebel, Merja A. Neukamm, Christoph Bode, Alexander Supady, Achim Lother   +7 more
doaj   +1 more source

Prominent bradycardia in a COVID-19 patient receiving Remdesivir: a case report

Qanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, 2022
Remdesivir is a commonly used antiviral drug to treat COVID-19. Remdesivir has some side effects; however, whether it has any effect on cardiac is rarely reported.
Sidhi Laksono Purwowiyoto, Grace Trifena Hosea   +1 more
doaj   +1 more source

Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

Pharmaceutics, 2020
Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry powder for inhalation using thin film freezing (TFF).
Sawittree Sahakijpijarn, Chaeho Moon, John J. Koleng, Dale J. Christensen, Robert O. Williams   +4 more
doaj   +1 more source

Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate

Journal of Microbiology, Immunology and Infection, 2023
Background: Despite increasing concerns about the association between remdesivir and bradycardia in severe coronavirus disease 2019 (COVID-19) patients receiving remdesivir, information on its clinical course and precipitating factors is limited. Our aim
Yan-Zuo Chen, Ming-Shen Lin, Yi-Ping Lin, Yi-Zhan Liu, Chia-Jui Yang   +4 more
doaj   +1 more source

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study

Infectious Diseases and Therapy, 2023
Introduction In the PINETREE study, early remdesivir treatment reduced risk of coronavirus disease 2019 (COVID-19)-related hospitalizations or all-cause death versus placebo by 87% by day 28 in high-risk, non-hospitalized patients. Here we report results
Samuel M. Brown, Morgan J. Katz, Adit A. Ginde, Kavita Juneja, Monica Ramchandani, Joshua T. Schiffer, Carlos Vaca, Robert L. Gottlieb, Yuan Tian, Emon Elboudwarej, Joshua A. Hill, Richard Gilson, Lauren Rodriguez, Charlotte Hedskog, Shuguang Chen, Jairo M. Montezuma-Rusca, Anu Osinusi, Roger Paredes   +17 more
doaj   +1 more source

The effect of remdesivir on selective biomarkers and its value in predicting the clinical outcome in patients with COVID-19

Asian Journal of Medical Sciences, 2021
Background: To the best of our knowledge, there have been no studies to evaluate the effect of remdesivir on inflammatory markers. Aims and Objectives: To study the effect of Remdesivir on Selective biomarkers namely C-Reactive Protein (CRP), Lactate ...
Sanjana Rai , Dyna Jones , Chinnappa Anjanappa Jayashankar , Venkata Bharat Kumar Pinnelli , Eashwer Manpreeth , Venkata Sai Raghava Prashanthi Seetha   +5 more
doaj   +1 more source